Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Taking Flexible Approaches towards Patients Enrolled in Clinical Studies amid COVID-19 Pandemic
May 15, 2020
- Denka to Start Production of Raw Material for Avigan from May 16
May 15, 2020
- Eisai Resurrects Eritoran as Potential COVID-19 Treatment, Eyes Trial Launch Next Month
May 14, 2020
- Takeda Exec Says Plasma Alliance Could Start Clinical Trial for Unbranded Therapy in July
May 14, 2020
- Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%
May 14, 2020
- Eisai Chalks Up Record Profits on Lenvima Boon
May 14, 2020
- Ono to Establish Subsidiary in US to Manage New Venture Investment Fund
May 14, 2020
- Nippon Shinyaku Starts Enrolling Patients in Multinational PIII of Viltolarsen
May 14, 2020
- Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US
May 14, 2020
- Sumitomo Dainippon’s FY2019 Sales Up 5.1% on Equa/EquMet Addition
May 14, 2020
- Roche Diagnostics Rolls Out Coronavirus Antibody Detection Reagents in Japan
May 14, 2020
- Ono to Test Pancreatitis Med Foipan for COVID-19: President
May 13, 2020
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Xofluza Sees Sharp Sales Decline, but Inavir Logs Growth: 2019-2020 Flu Drug Market
May 13, 2020
- Keytruda Keeps Top Spot in April Drug Ranking: Encise
May 12, 2020
- Shionogi Suffers Lower Earnings as Xofluza Sales Dive 98.4% in FY2019
May 12, 2020
- Santen Snaps Up Exclusive Rights for US Biotech’s Eye Cell Therapy in Japan, Asia, Europe
May 12, 2020
- Daiichi Sankyo Chairman Nakayama to Step Aside as Adviser
May 12, 2020
- Mylan EPD Curbing Nesp Biosimilar Supplies amid Big Demand
May 11, 2020
- Novartis Offers Free Access Program for Zolgensma Diagnostic
May 11, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…